fllwrs – keep track of who follows and unfollows you on twitter
the easiest way to track your twitter followers
Related Articles
EHA 2024 Interview: Saskia Middeldorp
I worked in a breast cancer laboratory at the National Cancer Institute (NCI), Bethesda, Maryland, USA, during the summer after my first…
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial
In women with a history of venous thromboembolism, weight-adjusted intermediate-dose low-molecular-weight heparin during the combined antepartum and post-partum periods was not associated with a lower…
Ik ga op vakantie en er is een tijdsverschil. Op welk tijdstip moet ik mijn antistollingsmiddel innemen?
Pati ënt / Ontspanning, sport en vakantie / Ik ga op vakantie en er is een tijdsverschil. Op welk tijdstip moet ik mijn antistollingsmiddel innemen?…
American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing
Conclusions. Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is contro
Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank
Population-scale genomics (N = 937 939) allowed assembly of a large FVL/PTGM double-heterozygous cohort while mitigating ascertainment bias.FVL/PTGM DH app
Double-heterozygous FVL/PTGM: double the trouble
In this issue of Blood, Ryu and colleagues1 provide definitive data on the risk of venous thromboembolism (VTE) in individuals who are double heterozygous
Vacature – Internist – chef de clinique (duobaan)
De chefs de clinique interne geneeskunde zorgen samen voor de kwaliteit en continuïteit van zorg op de verpleegafdeling Interne Geneeskunde, 5 …
Thrombophilia testing: Who to test and when? | COR2ED
Which types of patients can benefit from thrombophilia screening? How should HCPs interpret the results, and do they impact therapeutic management? What
Update on Andexanet Alfa for Reversal of FXa Inhibitors: Annexa-I Trial Webinar
Date: April 30, 2024Presenters: Jean Connors, MD; Jori May, MD; Ashkan Shoamanesh, MD; Deborah Siegal, MD, MSc, FRCPC; Jerrold Levy, MD, FAHA, FCCMFor more i…
Update on Andexanet Alfa for Reversal of FXa Inhibitors: Annexa-I Trial Webinar
Date: April 30, 2024Presenters: Jean Connors, MD; Jori May, MD; Ashkan Shoamanesh, MD; Deborah Siegal, MD, MSc, FRCPC; Jerrold Levy, MD, FAHA, FCCMFor more i…